Showing 2251-2260 of 5644 results for "".
- Ciliatech Raises Money to Advance Development of Disruptive Glaucoma Implanthttps://modernod.com/news/ciliatech-raises-money-to-advance-development-of-disruptive-glaucoma-implant/2481560/Ciliatech announced it has raised €3.5M (about $4 million) to advance the company's glaucoma implant, CID (Cilio-scleral Inter-positioning Device), a technology that aims to disrupt traditional approaches in glaucoma surgery. Ciliatech says CID differs from other glau
- New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgeryhttps://modernod.com/news/new-trefoil-therapeutics-data-presented-at-arvo-demonstrate-that-tthx1114-controls-edema-in-at-risk-patients-undergoing-cataract-surgery/2481556/Trefoil Therapeutics announced a series of data presentations demonstrating the potential use of TTHX1114 to protect endothelial cells at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The company also announced the completion of the phase 1 epithel
- Bausch + Lomb Announces U.S. Launch of StableVisc Cohesive Ophthalmic Viscosurgical Device and TotalVisc Viscoelastic Systemhttps://modernod.com/news/bausch-lomb-announces-us-launch-of-stablevisc-cohesive-ophthalmic-viscosurgical-device-and-totalvisc-viscoelastic-system/2481555/Bausch + Lomb announced the US launch of StableVisc cohesive ophthalmic viscosurgical device (OVD) and the TotalVisc Viscoelastic System. StableVis
- One Million Patients Measured on the Neurolens Measurement Devicehttps://modernod.com/news/one-million-patients-measured-on-the-neurolens-measurement-device/2481546/Neurolens announced that 1 million patients have been measured on the Neurolens Measurement Device, an eye tracking system that can identify eye misalignment as small as 0.01 prism diopters. Given the sharp acceleration in remote working and learning, optometrists have reported record number
- CORE Demonstrates Advanced 3D Printing for Ocular Research at ARVO 2023https://modernod.com/news/core-demonstrates-advanced-3d-printing-for-ocular-research-at-arvo-2023/2481539/Scientists from the Centre for Ocular Research & Education (CORE) plan to unveil multiple advancements in 3D printing during the ARVO 2023 Annual Meeting in New Orleans. These innovations may widespread applications, with the potential to accelerate dev
- Allegro Ophthalmics Receives Approval from FDA for Design of Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-receives-approval-from-fda-for-design-of-phase-2b3-clinical-trial-of-risuteganib-for-the-treatment-of-intermediate-dry-amd/2481527/Allegro Ophthalmics announced that the company has received agreement from the FDA under a Special Protocol Assessment (SPA) for the design of its phase 2b/3 clinical trial of risuteganib (Luminate) for the treatment of intermediate, dry age-related macular degeneration (AMD).
- Kala Receives FDA Fast Track Designation for Human MSC-S Therapy for Persistent Corneal Epithelial Defecthttps://modernod.com/news/kala-pharmaceuticals-receives-fda-fast-track-designation-for-kpi-012-a-human-msc-s-therapy-for-persistent-corneal-epithelial-defect/2481526/The FDA has granted Fast Track designation for Kala Pharmaceuticals' human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of persistent corneal epithelial defect (PCED). “There is a significant unmet need for patients suffering from PCED, whic
- Radius Announces Software Upgrade for Wearable Device for Perimetric Examinationshttps://modernod.com/news/radius-announces-perimeter-software-upgrade-for-wearable-device/2481518/Radius XR has launched its Radius 1.0 software release for perimetric examinations. Its interface is designed to assist eye care practices in delivering more comprehensive glaucoma management. Radius is a portable Vision Diagnostic and Patient Engagement system that combi
- Pixium Vision Announces FDA Breakthrough Device Designation for the Prima System in Dry AMDhttps://modernod.com/news/pixium-vision-announces-fda-breakthrough-device-designation-for-the-prima-system-in-dry-amd/2481505/The FDA has granted Breakthrough Device Designation to Pixium Vision's Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision implanted in human patients with atrophic dry age-related macular
- Théa Open Innovation and Galimedix Partner to Develop and Commercialize GAL-101 for Ophthalmic Indicationshttps://modernod.com/news/thea-open-innovation-and-galimedix-partner-to-develop-and-commercialize-gal-101-for-ophthalmic-indications/2481497/Théa Open Innovation and Galimedix Therapeutics announced that they have signed a licensing agreement in which Galimedix will grant Théa exclusive rights for the development and commercialization of GAL-101, Galimedix’s lead disease-modifying compound, for the topical and